


Details:
Through the acquisition, Organon will also acquire Forendo’s pipeline including it's lead candidate, FOR-6219, an investigational, potentially first-in-class oral 17beta-hydroxysteroid dehydrogenase type 1 inhibitor entering Phase 2 clinical development for endometriosis.
Lead Product(s): FOR-6219
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FOR-6219
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Organon
Deal Size: $945.0 million Upfront Cash: $75.0 million
Deal Type: Acquisition December 13, 2021
Details:
Acquisition of Forendo further demonstrates Organon's commitment to build a pipeline of impactful treatment options for women with unmet medical needs, which include Forendo’s lead investigational clinical compound, FOR-6219.
Lead Product(s): FOR-6219
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FOR-6219
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Organon
Deal Size: $945.0 million Upfront Cash: $75.0 million
Deal Type: Acquisition November 11, 2021
Details:
Cannabidiol, is the second most prevalent active ingredient in cannabis (marijuana) used for anxiety, pain, a muscle disorder called dystonia, Parkinson disease, Crohn disease, and many other conditions.
Lead Product(s): Cannabidiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Company’s proposed pharmaceutical, Cannabinoid based, chewing Gum product (sublingual absorption-delivery system) under development for the treatment of nausea derived from active chemotherapy treatment.
Lead Product(s): Cannabidiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Details:
The Company’s proposed Cannabidiol delivery system (via: sublingual absorption / oral mucosa), utilizes its proprietary Cannabidiol infused chewing gum platform.
Lead Product(s): Cannabidiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Institutional Review Board
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 13, 2021
Details:
The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo’s therapeutic concept.
Lead Product(s): FOR-6219
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FOR-6219
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
While MLE-301 was generally well-tolerated, the data do not support moving forward with its development in the target population of peri- and post-menopausal women, especially with the evolving dynamics of a highly competitive NK3R antagonist market.
Lead Product(s): MLE-301
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
The single ascending dose portion of the study will be conducted in healthy male volunteers, to determine the pharmacokinetics of MLE-301 and its pharmacodynamic profile as measured by reductions of biomarkers (luteinizing hormone, testosterone).
Lead Product(s): MLE-301
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020